Archive - 2013

12 November 2013 - Press Releases

Karus Therapeutics Appoints Penelope Ward as CMO

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced that Penelope Ward has joined the Company in the role of Chief Medical Officer. Her appointment strengthens the Company’s expansion which recently saw the formation of a Scientific Advisory Board, appointment of additional R&D personnel and a move to a world-class biotech hub near Oxford.

Read more

Events

29-30 Oct 2013
SciBX Summit on Innovation in Drug Discovery and Development 2013, Boston, MA, USA

02 October 2013 - Press Releases

Karus Therapeutics wins ‘Best Biotech Fundraiser’ award

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has won ‘Best Biotech Fundraiser’ at this year’s OBN Awards ahead of shortlisted candidates e-Therapeutics and Heptares Therapeutics.

Read more

Events

1 Oct 2013
OBN Awards Dinner, Oxford, UK

26 September 2013 - Press Releases

Karus Therapeutics shortlisted for key industry award

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, is shortlisted for the ‘Best Biotech Fundraiser’ at this year’s OBN Awards. The awards will be held on the 1st October 2013 at the Ashmolean Museum in Oxford and will bring together the UK's emerging life sciences companies, corporate partners and investors to celebrate the achievements within the bioscience sector over the last year. To read more about the OBN Awards, please follow the link here.

Read more

21 August 2013 - Press Releases

Karus Therapeutics secures prominent role in epigenetics debate at SciBX Summit 2013

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced its engagement with the “Epigenetics’ Second Wind” debate at the SciBX Summit on Innovation in Drug Discovery and Development to be held in Boston, USA, on 29-30 October.

Read more

17 July 2013 - In the News

Karus Therapeutics interviewed by Pharma Television

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was interviewed about its pioneering work in the HDAC and PI3K arena. Dr Simon Kerry, Karus’s CEO discussed the Company’s plans to develop current programmes using its substantial financing backing with Pharma Television’s Fintan Walton at the 10th Anglonordic Biotech Conference, London, UK. To watch the interview, please follow the link here.

Read more

Events

10-11 July 2013
BIA UK CEO and Investor Forum 2013,  Hatfield Heath, Hertfordshire, UK

Events

10-11 July 2013
BIA UK CEO and Investor Forum 2013, Hatfield Heath, Hertfordshire, UK

Events

17-19 June 2013
Next-Gen Kinase Inhibitors, Boston, USA

Events

13 June 2013
10th Anglonordic Biotech Conference, London, UK

15 May 2013 - In the News

Karus Therapeutics features on BBC South News

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, was featured on BBC South Today to highlight the importance of attracting venture capital financing to support the research and development of early stage biotechnology companies in the Oxfordshire area. The news story included filming at the new Karus laboratories in Milton Park and interviews with Dr Simon Kerry, CEO and Dr Stephen Shuttleworth, CSO.

Read more

Events

14-16 May 2013
BioTrinity 2013, Newbury, Berkshire, UK

19 April 2013 - Press Releases

Karus Therapeutics presenting at BIO, BioTrinity, Anglo-Nordic Biotech and Next-Gen Kinase Inhibitors

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be making presentations at a number of key trade conferences including:

Read more

09 April 2013 - Press Releases

Karus Therapeutics appoints Scientific Advisory Board and announces move to new Oxford facilities

Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, today announced the appointment of its scientific advisory board (SAB), which brings together world-leading expertise in target biology and drug research and development. The appointment of Karus’s SAB reflects the Company’s recent expansion and move to fully-integrated research and office facilities near Oxford.

Read more